Emmaus Life Sciences, Inc. (EMMA)

Market Cap	902.10K
Revenue (ttm)	16.55M
Net Income (ttm)	-4.44M
Shares Out	63.87M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	25,257
Open	0.0141
Previous Close	0.0141
Day's Range	0.0141 - 0.0141
52-Week Range	0.0001 - 0.0957
Beta	7.64
RSI	45.11
Earnings Date	Sep 10, 2025

About Emmaus Life Sciences

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Its pipeline products include ELS004, a pharmaceutical grade L-glutamine that is in Phase 1 clinical trial to treat diverticulosis. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 35
• Stock Exchange: OTCMKTS
• Ticker Symbol: EMMA

Financial Performance

In 2024, Emmaus Life Sciences's revenue was $16.65 million, a decrease of -43.73% compared to the previous year's $29.60 million. Losses were -$6.45 million, 72.9% more than in 2023.